Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 18/20 | 0.51 |
| ▸ | SLC6A4 | P31645 | 18/20 | 0.51 |
| ▸ | SLC6A3 | Q01959 | 13/20 | 0.51 |
| ▸ | KCNH2 | Q12809 | 6/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4458754 | 1.00 | SLC6A2 (0.51) | SLC6A2SLC6A4SLC6A3KCNH2CYP2D6 | |
| SCHEMBL8282231 | 0.85 | SLC6A2 (0.46) | SLC6A2SLC6A4SLC6A3KCNH2CYP2D6 | |
| SCHEMBL4463752 | 0.78 | SLC6A4 (0.51) | SLC6A2SLC6A4SLC6A3KCNH2CYP2D6 | |
| SCHEMBL4463758 | 0.78 | SLC6A4 (0.51) | SLC6A2SLC6A4SLC6A3KCNH2CYP2D6 | |
| SCHEMBL853339 | 0.77 | SLC6A1 (0.44) | SLC6A2SLC6A4SLC6A3KCNH2CYP2D6 | |
| Hydrochloric Acid SCHEMBL6313494 | 0.76 | SLC6A1 (0.43) | SLC6A2SLC6A4SLC6A3KCNH2CYP2D6 | |
| SCHEMBL10868813 | 0.75 | SLC6A1 (0.53) | SLC6A2SLC6A4SLC6A3KCNH2CYP2D6 | |
| SCHEMBL4441414 | 0.75 | SLC6A1 (0.53) | SLC6A2SLC6A4SLC6A3KCNH2CYP2D6 | |
| SCHEMBL5634353 | 0.74 | SLC6A2 (0.41) | SLC6A2SLC6A4SLC6A3KCNH2CYP2D6 | |
| SCHEMBL3619850 | 0.74 | SLC6A4 (0.48) | SLC6A2SLC6A4SLC6A3KCNH2CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7507760-B2 | N-type calcium channel blockers | NEUROMED PHARMACEUTICALS LTD. (CA) | 2009-03-24 | — | — | US | disclosed |
| US-7507760-B2 | N-type calcium channel blockers | NEUROMED PHARMACEUTICALS LTD. (CA) | 2009-03-24 | — | — | US | disclosed |
| US-7507760-B2 | N-type calcium channel blockers | NEUROMED PHARMACEUTICALS LTD. (CA) | 2009-03-24 | — | — | US | disclosed |
| EP-1718633-A1 | N-TYPE CALCIUM CHANNEL BLOCKERS | Neuromed Pharmaceuticals, Ltd. (CA) | 2006-11-08 | — | — | EP | disclosed |
| WO-2005070919-A1 | N-TYPE CALCIUM CHANNEL BLOCKERS | NEUROMED PHARMACEUTICALS LTD. (CA) | 2005-08-04 | — | — | WO | disclosed |
| US-20050165065-A1 | N-type calcium channel blockers | ZALICUS PHARMACEUTICALS LTD. (CA) | 2005-07-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050165065-A1 | N-type calcium channel blockers | CACNA1B, CACNA1C, CACNA1D | SLC6A2 731/4885SLC6A4 397/4885SLC6A3 699/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.